Sort   by:  
 Page size 
UnknownMET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Not available
S-EPMC3255989 | biostudies-literature
UnknownClinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Not available
S-EPMC4451171 | biostudies-literature
UnknownAn inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.
Not available
S-EPMC8014813 | biostudies-literature
UnknownLOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
Not available
S-EPMC10106481 | biostudies-literature
UnknownLorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Not available
S-EPMC5777233 | biostudies-literature
UnknownA Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Not available
S-EPMC10011885 | biostudies-literature
Genomics4dbf9af0-d667-494b-b3d9-c80c112d0527 - samples
high depth WGS sequencing of 8 sites of a RET fusion tumour
EGAD00001006878 | EGA
Genomicsdc7d6e29-28d7-43ec-895c-d530c18112cf - samples
Deep WGS sequencing (160x) of 2 different sites of disease of a patient with a RET fusion positive cancer. Amplicon sequencing of 19 other sites of the same patients for the RET fusion.
EGAD00001005776 | EGA
GenomicsMulti-regional tumour biopsies of a RET fusion patient
Identifying modes of resistance to a new experimental drug for a patient resistant to other therapies
EGAS00001004023 | EGA
GenomicsPeter MacCallum Cancer Centre Research Data Access Committee
Data Access Committee EGAC00001001404
EGAC00001001404 | EGA
Sort   by:  
 Page size